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Antiviral agentsomplex of inﬂuenza A virus consists of three subunits PB1, PB2 and PA. Recently,
the cellular chaperone Hsp90 was shown to play a role in nuclear import and assembly of the trimeric
polymerase complex by binding to PB1 and PB2. Here we show that Hsp90 inhibitors, geldanamycin or its
derivative 17-AAG, delay the growth of inﬂuenza virus in cell culture resulting in a 1–2 log reduction in viral
titre early in infection. We suggest that this is caused by the reduced half-life of PB1 and PB2 and inhibition of
nuclear import of PB1 and PA which lead to reduction in viral RNP assembly. Hsp90 inhibitors may represent
a new class of antiviral compounds against inﬂuenza viruses.
© 2008 Elsevier Inc. All rights reserved.IntroductionTheRNA-dependent RNApolymerase of the inﬂuenzaAvirus (FluA)
is a heterotrimeric complex consisting of the PB1, PB2, and PA subunits.
The trimeric complex catalyzes viral RNA transcription and replication
in the nucleus of infected cells. Recently, we (Deng et al., 2005; Mayer
et al., 2007) and others (Kawaguchi and Nagata, 2007; Momose et al.,
2002) have identiﬁed several cellular proteins that associate with the
trimeric polymerase complex or its individual subunits. One of these
proteins, heat shock protein 90 (Hsp90), was reported to bind to the
PB1 and PB2 polymerase subunits (Naito et al., 2007). It has been
suggested thatHsp90 is involved in the assembly andnuclear transport
of viral RNA polymerase subunits, possibly as a molecular chaperone
for the polymerase subunits prior to the formation of a mature ternary
polymerase complex (Naito et al., 2007).
Hsp90 is an atypical member of the family of heat shock-induced
chaperones (Pearl and Prodromou, 2006; Whitesell and Lindquist,
2005). It binds to a speciﬁc set of client proteins, including intracellular
receptors and signal transduction proteins, and facilitates their folding
presumably through domain rearrangement (Pearl and Prodromou,
2006; Whitesell and Lindquist, 2005). This chaperone activity iscted at Fax: +44 1865 275556.
burg.de (M. Schwemmle),
l rights reserved.dependent on various co-chaperones andATP (Whitesell and Lindquist,
2005). Hsp90 activity can be inhibited by drugs which compete for its
N-terminal ATP-binding site. These drugs include natural products
(radicicol, geldanamycin) and semi-synthetic or synthetic compounds
[e.g.17-allylamino-demethoxygeldanamycin (17-AAG), a geldanamycin
(GA) analogue] (Whitesell and Lindquist, 2005).
In this study, we report that Hsp90 inhibitors GA and 17-AAG delay
viral growth in cell culture. We observed a reduction of viral
transcription and replication with GA treatment in a concentration
dependent manner in virus infected cells. By studying the ribonu-
cleoprotein complex (RNP) formation, nuclear transport and protein
stability of polymerase subunits in transiently-transfected cells, we
suggest that inhibition of virus growth was due to both a reduced
half-life of PB1 and PB2 and an inhibition of nuclear import of PB1 and
PA. This leads to a reduction in viral RNP assembly. This conclusion is
consistent with the observation that reduced amounts of viral
polymerase complex were detected with the GA treatment in the
nucleus of infected cells.
Results
No cytopathic effects were observed with the Hsp90 inhibitors, GA and
17-AAG, at the concentrations used in this study
We ﬁrst systematically analyzed the toxicity of both Hsp90
inhibitors (GA and 17-AAG) by the MTT toxicity assay (see Materials
and methods) in the three different cell lines (MDCK, 293T and A549)
Fig. 1. Lack of toxicity of GA and 17-AAG. MDCK (A), 293T (B), or A549 (C) cells were
seeded in 96-well plates. Cells were then treated with the concentrations of inhibitors
or solvent, as shown, for 24 h, and metabolic activity was measured using an MTT kit as
described in Materials and methods. Hydrogen peroxide (H2O2) was used as a control to
induce cell death. The absorbance at 570 nm of DMSO-treated cells was arbitrarily set to
100%. Values represent the mean of three independent experiments, and error bars
show the standard deviation of the mean.
432 G. Chase et al. / Virology 377 (2008) 431–439which were used in this study. The MTT assay measures the metabolic
activity of cultured cells using a colorimetric substrate, which is a
well-known cytotoxicity marker (Mosmann, 1983). As shown in Fig. 1,
no signiﬁcant toxicity was observed at concentrations of GA from 200
to 800 nM and at concentrations of 17-AAG from 200 to 1000 nM in all
three cells lines. Therefore, we performed future experiments with GA
at concentrations no higher than 800 nM, and with 17-AAG at con-
centrations no higher than 1000 nM.Hsp90 inhibitors delay viral growth
We next tested whether the Hsp90 inhibitors, GA and 17-AAG, were
able to block viral multiplication in cell culture. MDCK cells were infected
with inﬂuenza A virus (A/WSN/33) at a multiplicity of infection (m.o.i.) of
0.01. One hour post infection (p.i.), cells were washed and incubated for
further 23 hwithmedia containing solvent (DMSO) or various amounts of
Hsp90 inhibitors (GA and17-AAG). Viral titres were determined by plaque
assay (Cooper, 1967). Fig. 2A showed that the inhibition was most
pronounced at 800 nMGA and at 1 μM17-AAG. The kinetics of inhibition
of virus multiplication with 800 nM GA (upper panel) and with 1 μM 17-
AAG treatment (lower panel) is shown in Fig. 2B. Similar results were
obtained using several other FluA strains including a distantly related
H7N7 strain (SC35M, data not shown).We conclude that Hsp90 inhibitors
inhibit viral growth at early time points.
Hsp90 inhibitors delay accumulation of viral mRNA, cRNA and vRNA
To determine whether viral transcription and/or replication is
affected by Hsp90 inhibitors, 293T cells were infected with A/WSN/33
virus (m.o.i.=6) in the presence of GA or a DMSO control. Cells were
harvested at 3, 6 and 9 h p.i. and total RNA was isolated (see Materials
and methods). The levels of the three species of viral RNAs, mRNA, cRNA
and vRNA, synthesized from the neuraminidase (NA) segment and the
host cell derived 5S rRNA (Hara et al., 2006). were determined by
primer extension (Fodor et al., 2002; Vreede et al., 2004) (Fig. 3A) and
quantitated (Figs. 3B–D). Increasing amounts of GAup to 400 nM resulted
in adelayed synthesis ofNAmRNA, cRNAandvRNA. Indetail, at 3hp.i.,we
observed adecrease in all threeRNAspecies. At later timepoints, however,
therewas a reduction of cRNA (Fig. 3C) and vRNA levels (Fig. 3D) but not of
mRNA levels, although thepeak levels ofmRNAweredelayed compared to
the DMSO control (Fig. 3B, see Discussion).
Accumulation of viral RNAs is inhibited by Hsp90 inhibitors in a RNP
reconstitution assay
A preliminary experiment, using a FluA minireplicon assay with a
ﬁreﬂy luciferase reporter gene to test the effect of Hsp90 inhibitors on the
reconstitutedviral polymerase in293Tcells (Ghanemet al., 2007), showed
that 400 nM GA signiﬁcantly reduced reporter activity (data not shown).
Next we performed a RNP reconstitution experiment to test the effect of
GAon individual viral RNA species. 293Tcellswere transfectedwith Pol II-
driven pcDNA expression plasmids coding for PB1, PB2, PA and NP (Fodor
et al., 2002) and a Pol I-driven expressionplasmid coding for the inﬂuenza
A virus NA vRNA segment (Pleschka et al., 1996) in the presence of
increasing amounts of GA. The three species of viral RNAs were analyzed
by primer extension at 24 h post-transfection (Fodor et al 2002). Fig. 3A
(raw data) and B (quantitated) showed that increasing amounts of GA
resulted in a dose-dependent reduction in all three viral RNA species —
speciﬁcally mRNA, cRNA and vRNA, suggesting that accumulation of viral
RNAs is dependent on Hsp90 function.
GA inhibits RNP formation
The decrease in all three viral RNA species observed in Fig. 4A may
result from a decrease in RNP formation in GA treated cells. To directly
test this hypothesis, we reconstituted a viral RNP containing TAP-tagged
NP in 293T cells with GA treatment (200 nM and 400 nM) or DMSO
control and performed TAP puriﬁcation (Deng et al., 2005) at different
times post transfection (13 and 20 h). This procedure is known to be
speciﬁc for the TAP tag since no detectable nonspeciﬁc pull-down of
individual polymerase subunits by IgG Sepharose was observed before
(Deng et al., 2005). Moreover it is known that TAP-tagged NP retains
signiﬁcant replication and transcription activities compared towild type
in reconstituted RNP when assayed by primer extension (Vreede and
Brownlee, 2007). After TAP puriﬁcation of the RNPs, the association of
Fig. 2.Hsp90 inhibitors delay growth of inﬂuenza A virus in cell culture. A) Effect of Hsp90 inhibitors (GA and 17-AAG at various concentrations) on virus titres in MDCK cells infected
with inﬂuenza A virus (A/WSN/33) at m.o.i.=0.01. B) Effect of GA (800 nM) and 17-AAG (1000 nM) on kinetics of viral growth. MDCK cells were infected and subsequently incubated
with GA or 17-AAG or solvent (DMSO). Viral titres were determined by plaque assay at 24 h (A) or the indicated time points (B) p.i. Values represent the mean of three independent
experiments, and error bars show the standard deviation of the mean.
433G. Chase et al. / Virology 377 (2008) 431–439viral polymerase with the RNP complexes was determined by Western
blot analysis.We used PA, rather than PB1 and PB2 antibody to estimate
the level of the reconstituted RNP complex because known speciﬁc
interactions between free NP and either PB1 or PB2 precludes using
these antibodies (Biswas et al., 1998; Medcalf et al., 1999). As shown in
Fig. 4C (ii), there is a signiﬁcant reduction in the amount of co-puriﬁed
PA in cells treated with GA compared to untreated cells, despite similar
amounts of puriﬁed TAP-NP (iii) and similar amounts of PA (i) in the
crude cell extracts from both treated and untreated cells. We also
analysed the activity of the puriﬁed RNPs in an in vitro ApG-primed
transcription assay (see Materials and methods) in the absence of UTP
giving rise to a 14 nt long partial transcript from endogenous, viral NA
template present in the RNP complex. Any cRNP puriﬁed with the vRNP
would not be transcribed in the ApG-primed transcription assay in the
absence of UTP, because UTP is required at nucleotide 3 immediately
following the ApG primer (Deng et al., 2006). As expected, lower yields
of transcripts were produced with TAP-puriﬁed vRNPs from GA-treated
cells, compared to vRNPs from untreated cells [Fig. 4C (iv)]. Somewhat
surprisingly the inhibition by GA was apparently more pronounced in
the puriﬁed RNPs when assayed for enzymatic activity by ApG-primed
transcription [Fig. 4C (iv)] than when mRNA was assayed in recon-
stituted RNP by primer extension (Fig. 4B). The reasons for this are
unknown but may reﬂect the different assays used (mRNA levels versus
protein activity) or the slightly different times of transfection. However,
ApG-primed transcription of puriﬁed vRNPs in vitro is not blocked by
GA (Fig. 4D). Overall, these results indicate that formation of active
vRNPs is hindered by treatment with GA, but GA does not inhibit the
preformed complex.
In order to exclude the possibility that the effect of GA observed
(Figs. 4A–C) was caused by GA directly inhibiting host Pol I or Pol II,
293T cells were transfected with either pPol I-NA (Fig. 4E), or the Pol
II-driven expression plasmid, pcDNA-NA (Fig. 4F). The pPOl I- and Pol
II transcripts were then analysed by primer extension (see Materials
and methods) at different time post-transfection (13 and 20 h).Quantitation of the three experiments indicates no inhibition of Pol I
or Pol II transcription.
Hsp90 inhibitors enhance the degradation of PB1 and PB2
It has been shown that GA and 17-AAG can prevent the release of
client proteins from Hsp90, which eventually leads to their degrada-
tion by the proteasome (Pearl and Prodromou, 2006). The simplest
explanation of the observed inhibition of FluA by GA or 17-AAG is thus
an enhanced degradation of viral proteins which happen to be Hsp90
clients. To test this hypothesis, we performed pulse-chase experi-
ments as shown in Fig. 5 (upper panel). Preliminary experiments had
shown that individually expressed polymerase PB1 and PB2 subunits
had a very short half life (b2 h); therefore, a short, 1 h chase was
optimal for our experiments. Quantitation showed that PB2 is
preferentially degraded with increasing concentrations of inhibitor,
and PB1 is degraded only at the highest concentration of inhibitor,
whereas PA was unaffected (Fig. 5). This selectivity for PB1 and PB2,
but not PA, correlates with the observation that both PB1 and PB2 bind
to Hsp90 [(Naito et al., 2007), data not shown]. Therefore, these results
support the hypothesis that PB1 and PB2 are client proteins of Hsp90.
Thus Hsp90 inhibitors can enhance the degradation of PB1 and PB2.
GA treatment reduces nuclear accumulation of PA and PB1, but not PB2
Recently it has been reported that Hsp90 may be important for the
nuclear import of inﬂuenza polymerase subunits (Naito et al., 2007).We
thus analyzed the intracellular localization of the three individually
expressed subunits in 293T cells, in the presence or absence of 500 nM
GAusingGFP fusionproteinswhichdistribute similarly to their untagged
counterparts (Fodor and Smith, 2004). We observed a signiﬁcant
cytoplasmic retention of PB1, and to our surprise also PA (see below),
but not PB2 (Fig. 6). The ﬁnding that PB2 localizationwas not affected by
GA was unexpected since PB2 is an Hsp90 client protein. We can only
Fig. 3. Effect of GA on accumulation of viral RNAs in inﬂuenza A virus (A/WSN/33) infected 293T cells. A) Primer extension assays of vRNA, mRNA, and cRNA of NA segment at various
time points post-infection with DMSO, 200 nM or 400 nM GA. A longer exposure of the cRNA signal is shown below. B) Quantitation of viral mRNAs in GA-treated infected cells. The
radioactive signals corresponding to the viral mRNAs and 5S rRNA obtained in Awere quantiﬁed by phosphorimage analysis. Values were ﬁrst standardized to the 5S rRNA signal. The
three experiments were then normalized to one another by correcting for the different phosphoimaging exposure times in three different experiments. C) Quantitation of viral cRNAs
in GA-treated infected cells. D) Quantitation of viral vRNAs in GA-treated infected cells. Error bars in B, C and D are standard deviations of three independent experiments.
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ciently sensitive to detect a small increase in the levels of cytoplasmic
PB2 that would be expected in the presence of GA. The difﬁculty in
estimating cytoplasmic PB2 levels is compounded by the fact that
relatively low levels of PB2 are present in the cytosol, because of its
efﬁcient nuclear localization compared to PB1 and PA (Fodor and Smith,
2004). We also tested the effect of GA on intracellular localization of the
3P complex by co-transfecting three pcDNA plasmids expressing PB1-
GFP, PA, and PB2 in the presence or absence of 500 nMGA.We observed
only nuclear localization of the complex, as assayed by the GFP signal
(data not shown) in both treated and, as previously reported (Fodor and
Smith, 2004), in untreated cells. However, the GFP signal was generally
lower in cells treatedwith 500 nMGA than those treatedwith theDMSO
control (data not shown).
GA treatment reduces nuclear levels of 3P in infected cells
Since we have observed that GA treatment inhibits RNP formation
(Fig. 4), nuclear import of individually expressed PB1 and PA (Fig. 6),
and enhances the degradation of PB1 and PB2 (Fig. 5), we were
interested to test the intracellular localization of the viral polymerase
complex in infected cells. A549 cells were infected with inﬂuenza A
virus (A/WSN/33) at a multiplicity of infection of 2. Cells were
incubated with media containing solvent (DMSO) and with either
200 nM or 400 nM GA. At 9 h post-infection, the localization of the
polymerase complexes was examined by indirect immunoﬂuores-
cence (Fig. 7) (see Materials and methods). Consistent with thenuclear localization of the 3P complex in transfected cells (see above),
the PA subunit of the polymerase complex localized in the nucleus of
the infected A549 cells at 9 h post-infection in cells with orwithout GA
treatment. However, signiﬁcantly, the levels of PA in the nucleus were
reduced in a dose-dependent manner with the GA treatment
(compare Fig. 7 upper, middle and lower panels). The low levels of
PA and its ability to form a complex initially with PB1 in the cytosol
and subsequently with PB2 in the cell nucleus (Deng et al., 2005;
Fodor and Smith, 2004) might exclude detectable cytoplasmic
localization in the presence of GA in these infection experiments,
even though this was observed with individually transfected PB1 and
PA (Fig. 6, above).
Discussion
The aim of this workwas to test whether Hsp90 inhibitors could be
used as inﬂuenza antivirals since Hsp90 was known to play a role in
the nuclear import and assembly of the trimeric polymerase complex
(Naito et al., 2007). Here, we provide evidence that GA and 17-AAG
impair inﬂuenza viral growth by reducing the levels of ribonucleo-
protein complexes (Figs. 3 and 7). We speculate that the decrease in
the amounts of RNPs is due to selective degradation of the PB1 and
PB2 subunits in the presence of Hsp90 inhibitors (Fig. 5). This
observation correlates with our ﬁnding that less polymerase complex
is associated with TAP-NP in GA-treated cells (Fig. 4C), which suggests
that there are fewer trimeric complexes in the cell nucleus which are
competent to form ribonucleoprotein complexes. Moreover the
Fig. 4. Hsp90 inhibitors reduce RNP formation. A) GA reduces accumulation of viral RNAs in a RNP reconstitution assay. The positions of transcription products derived from NA
mRNA, cRNA, vRNA, and 5S rRNA, used as a control, are indicated on the right. A typical result of four experiments, harvested 24 h post-transfection, is shown. B) Quantitation of viral
RNAs in the presence of GA in the RNP reconstitution assay. An average of four experiments is shownwith standard deviations. Values were standardized to the 5S rRNA signal, and
values were expressed as % of the control values set to 100% (samples treated with DMSO). Values signiﬁcantly different from 100% (Pb0.05, Student's t test) are indicated by an
asterisk (⁎). C) GA inhibits RNP formation. The amount of PA in crude lysate (i) and in RNP (ii) was examined byWestern blot using a polyclonal anti-PA antibody (Hara et al., 2006).
The amount of TAP-NP (N-terminally tagged) present in the puriﬁed samplewas examined byWestern blotswith anti-NP antibody (iii). The activity of the puriﬁed RNPswas analysed
in vitro using an ApG-primed transcription assay (iv). The reaction contains [α-32P]-GTP,(iv). The 14 nt long transcription product (TP) is indicated on the right. D) GA does not inhibit
preformed RNP. An in vitro ApG-primed transcription assay (see iv above) using RNPs puriﬁed from the DMSO control sample [same sample used in Fig. 4C (iv) lane 4] was performed
in the presence of increasing concentrations of GA. E) GA does not inhibit Pol I transcription. Quantitation of 3 experiments analysing a Pol I NA transcript with DMSO, 200 nM or
400 nM GA treatment at 13 h and 20 h post-transfection by primer extension analysis. F) GA does not inhibit Pol II transcription. Quantitation of three experiments analyzing a Pol II
NA transcript with DMSO, 200 nM GA or 400 nM GA treatment at 13 h and 20 h post-transfection by primer extension analysis.
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could cause further reduction in the amount of RNPs available for viral
transcription and replication in the nucleus. Although there is no
evidence for an interaction between PA and Hsp90 [(Naito et al., 2007),
data not shown] it is possible that Hsp90 is required for a host function
supporting PAnuclear accumulation. However, we have been unable todetect signiﬁcantly less formation of recombinant trimeric polymerase
isolated by transient (37 h) transfection of GA-treated (either at 200 or
400 nM) 293T cells, using PB1, PA and a PB2-TAP tagged constructs of
inﬂuenza A/WSN/33 virus, by IgG afﬁnity methods (Deng et al., 2005)
(data not shown). Our failure to showsigniﬁcant differences in trimeric
polymerase levels in the presence of GA suggests that the expected
Fig. 5.Hsp90 inhibitors induce enhanced degradation of PB1 and PB2. Upper panel: 105 293Tcells were transfected with 2 μg pCA expression vectors coding either for HA-tagged PB1,
PB2 or PA and pulse-chased with 35S-labelled amino acids (cysteine andmethionine) as indicated in the presence of increasing concentrations of 17-AAG. Cell extracts were obtained
followed by immunoprecipitation of the individual subunits using agarose beads coupled to an anti-HA antibody. Lower panel: Protein levels from three independent experiments
were quantitated. Values are expressed as % of control (DMSO) levels. Error bars are the standard deviations; asterisks (⁎) indicate values signiﬁcantly different from 100% (Pb0.05,
Student's t test).
436 G. Chase et al. / Virology 377 (2008) 431–439reduction in trimeric polymerase may either be too small to detect
under the experimental conditions used or that other unknown effects
of GA may interfere with RNP assembly.
GA delays the accumulation of all 3 viral species (mRNA, cRNA and
vRNA), although the kinetics differ for the accumulation of mRNA
compared to that of cRNA and vRNA (Fig. 3). Speciﬁcally, in virus-Fig. 6. GA treatment reduces nuclear accumulation of PA and PB1, but not PB2. 293T cells we
GFP or PB2-GFP (Fodor and Smith, 2004) in the presence of 500 nM GA. At 16 h post transfec
(lower panels). Cells were scored for the localization pattern of the GFP-tagged polymerase su
cytoplasmic. The number of cells showing each localization patternwas expressed as % of the
patterns from three independent transfections with standard deviations is shown. Student's
signiﬁcantly different from the control values of DMSO-treated cells. Values that signiﬁcantinfected cells, the delay in mRNA synthesis is less marked than that of
vRNA and cRNA suggesting that GA inhibits replication more than
transcription. A possible explanation of this observation is as follows:
early after infection GA limits the amount of available inﬂuenza
polymerase thereby inhibiting the synthesis ofmRNA, cRNA and vRNA.
At later times, vRNA and cRNA accumulation aremore dependent thanre transfected with plasmids expressing GFP-tagged polymerase subunits PA-GFP, PB1-
tion, cells were ﬁxed with paraformaldehyde and analyzed by ﬂuorescence microscopy
bunit: N, predominantly nuclear; N/C, distributed throughout the cell; C, predominantly
total cell number (approximately 500 cells) (upper panels). The average % of localization
t test was performed to assess whether the values obtained in the presence of GAwere
ly differ from each other (Pb0.01) are indicated by an asterisk (⁎).
Fig. 7. GA treatment reduces nuclear accumulation of PA in infected cells. A) A549 cells were infected with inﬂuenza A/WSN/33 viruses at an m.o.i of 2 and were treated with DMSO,
200 nM or 400 nM GA. At 9 h post-infection, cells were ﬁxed and stained with a rabbit polyclonal anti-PA primary antibody and a Cy3-conjugated anti-rabbit secondary antibody.
Images were taken using confocal microscopy under 20× magniﬁcation with identical settings. B) Images of 200 nM GA sample were taken under 63× magniﬁcation with identical
setting to show the nuclear signals.
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needed to stabilize RNP (Vreede et al., 2004), whereas mRNA is
stabilized by host proteins. Alternatively, we speculate that, at later
time points, the inhibition of host Pol II by the inﬂuenza polymerase
(Engelhardt et al., 2005; Rodriguez et al., 2007) may be less marked
because of the limited amounts of inﬂuenza polymerase in the
presence of GA. Thus more host capped primers could be available
for the synthesis of viralmRNA, allowing its continued synthesis late in
infection. Overall our results are consistent with a previous study
which showed that GA can cause reduction in the levels of both PB2
and vRNA in FluA-infected cells (Dalton et al., 2006).There is ample evidence that Hsp90 inhibitors impair the growth
of many other viruses, including poliovirus (Geller et al., 2007),
vesicular stomatitis virus (VSV) (Connor et al., 2007) and hepatitis C
virus (Nakagawa et al., 2007). In the case of VSV, another negative-
strand RNA virus, GA caused a similar delay in viral multiplication as
observed here with FluA, although at early time points p.i. there was a
greater reduction in titres with VSV than FluA (Connor et al., 2007).
However, a direct comparison of titres is not possible due to the
different concentrations of GA used in the two studies. In all cases, the
inhibition was paralleled by enhanced degradation of viral proteins
which bind to Hsp90, such as polymerases (Connor et al., 2007) and
438 G. Chase et al. / Virology 377 (2008) 431–439capsid proteins (Geller et al., 2007). However, these studies, including
ours, cannot formally exclude the possibility that these effects are due
to the inhibition of Hsp90-dependent cellular functions that can
indirectly inﬂuence viral replication. Moreover, Hsp90 inhibitors could
have additional unrecognized effects. Nonetheless, as recently shown
for poliovirus infection (Geller et al., 2007), such low-toxicity
inhibitors may provide a new tool to interfere with viral infection.
Unlike existing ﬂuA antivirals (e.g. zanamivir, oseltamivir, amanta-
dine) which are designed to target inﬂuenza viral proteins (Palese and
Shaw, 2006), Hsp90 inhibitors, such as geldanamycin, 17-AAG or
improved more active derivatives, targeting a host factor may provide
a novel antiviral strategy not readily susceptible to the development of
drug resistance.
Materials and methods
Plasmids
The plasmids encoding PB1, PB2, PA and NP of inﬂuenza virus A/
WSN/33 (pcDNA-PB1, pcDNA-PA, pcDNA-PB1, pcDNA-PB2, pcDNA-NP,
pcDNA-TAP-NP pcDNA-PB1-GFP, pcDNA-PB2-GFP and pcDNA PA-GFP)
have been described previously (Deng et al., 2005; Engelhardt et al.,
2005; Fodor et al., 2002; Fodor and Smith, 2004). pPOLI-NA has also
been described (Pleschka et al., 1996). pcDNA-NA was derived from
pPOLI-NA by restriction with NgoMIV followed by the insertion of the
NA open reading frame of the NA gene of A/WSN/33 virus into the AgeI
site of pcDNA3A (Fodor et al., 2002). pCA-PA-HA, pCA-PB1-HA, and
pCA-PB2-HA have also been described previously (Ghanem et al.,
2007; Mayer et al., 2007).
MTT assay
The 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bro-
mide (MTT) assay measures the metabolic activity of cultured cells
using a colorimetric substrate (Mosmann, 1983). Cells were seeded
into 96-well plates and treated with GA (Invivogen) or 17-AAG
(Biomol). 24 h after treatment, cells were assayed for metabolic
activity using the MTT Cell Proliferation Kit I (Roche) according to
manufacturer's instructions.
Analysis of vRNA, mRNA and cRNA by primer extension assays
Primer extension analysis of neuraminidase (NA)-speciﬁc viral
RNAs was performed as described previously (Fodor et al., 2002;
Vreede et al., 2004). Transcription products were analyzed on 6%
polyacrylamide gels containing 7 M urea in Tris-borate-EDTA buffer
and were detected by autoradiography. The expected sizes of the
transcription products were 129 nucleotides (nt) (vRNA), 169 to 177 nt
(mRNA), and 160 nt (cRNA).
Puriﬁcation of reconstituted RNPs
Human embryonic kidney 293Tcells were transfectedwith pcDNA-
PA, pcDNA-PB1, pcDNA-PB2, pcDNA-TAP-NP and pPOLI-NA for 48 h to
express inﬂuenza RNA polymerase subunits, viral RNA template and
TAP-tagged NP. The RNP complexes were puriﬁed by using the TAP
method as described previously (Deng et al., 2005; Fodor and Smith,
2004; Puig et al., 2001). Brieﬂy, cell lysates prepared from transfected
293T cells were incubated with IgG-Sepharose and bound proteins
released by cleavage with tobacco etch virus (TEV) protease (Invitro-
gen). Puriﬁed protein samples were analyzed byWestern blotting. The
ApG-primed transcription assay [modiﬁed from (Fodor et al., 2002)] of
puriﬁed RNPs was performed in the presence of [α-32P]-GTP, ATP, CTP,
but in the absence of UTP, giving rise to a 14 nt long partial transcript
(AGCGAAAGCAGGAG) of endogenous, viral NA vRNA template present
in the RNPcomplex. Transcriptswere analysedby 16%PAGE in7Murea.Pulse-chase experiments
Transfected 293T cells were starved by incubation for 15 min with
DMEM without cysteine or methionine, then pulse-labelled 1.5 h in
the same medium containing 60 μCi/ml 35S-cysteine/methionine
(Amersham). Cells were then chasedwith complete DMEM containing
GA or 17-AAG for 1 h before lysis in RIPA buffer (50 mM Tris–HCl pH
8.0, 150 mM NaCl, 1% Nonidet P-40, 0.1% SDS, 0.25% sodium
deoxycholate) and incubation with anti-HA agarose (Sigma) for 2 h
at 4 °C. Beads were washed 4 times with RIPA buffer, resuspended in
loading buffer, separated by SDS-PAGE and labelled proteins visua-
lized by autoradiography and quantitated.
Localization of polymerase subunits in transfected cells
293T cells grown on 22×22 mm coverslips in six-well plates, were
transfected with plasmids expressing PB1-GFP, PA-GFP and PB2-GFP,
individually, in the presence or absence of 500 nM GA. At 16 h post-
transfection, cells were ﬁxed with 4% paraformaldehyde in 250 mM
HEPES (pH 7.5), and coverslips were mounted in Mowiol containing
4′,6′-diamidino-2-phenylindole. Cells were viewed by using a Zeiss
Axioplan microscope with a Zeiss×63 oil immersion objective with a
numerical aperture of 1.25, and the images were processed by using
Adobe Photoshop 7.0. For numerical analysis of polymerase distribu-
tion in transfected cells, 500 (for individually expressed PB1-GFP, PA-
GFP and PB2-GFP) ﬂuorescent cells per coverslip were examined and
scored according to whether the observed ﬂuorescence was pre-
dominantly cytoplasmic, nuclear or present throughout the cell.
Percentages of cells were calculated and expressed as an average from
three independent experiments.
Indirect immunoﬂuorescence
A549 cells grown on 13 mm coverslips in 24-well plates were
infected at an m.o.i of 2 in the presence DMSO or 200 nM or 400 nM
GA. At 6 and 9 h post-infection, the cells were ﬁxed with 2%
paraformaldehyde in phosphate-buffered saline (PBS). Following
ﬁxation, the cells were permeabilized with 0.1% Triton X-100 in PBS
for 10 min at room temperature, blocked and incubated with a rabbit
polyclonal PA antibody in PBS containing 3% bovine serum albumin for
1 h at room temperature. The cells were further incubated with Cy3-
conjugated anti-rabbit secondary antibody (Jackson ImmunoRe-
search) at a 1/400 dilution at room temperature for 1 h. Coverslips
were mounted in Mowiol. Cells were viewed by confocal microscopy
with a 20× or 63× objectives, and the images were processed by LMS
image browser.
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